DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Schmid P, Adams S, Rugo HS. et al.
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).
J Clin Oncol 2019;
37: 1003
doi:10.1200/JCO.2019.37.15_suppl.1003
Access:
We do not assume any responsibility for the contents of the web pages of other providers.